BioSpace News Archive

Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in two upcoming investor conferences in New York, NY.

OpGen, Inc., announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.

Context Therapeutics Inc. announced that Chief Executive Officer Martin Lehr will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference taking place virtually and in-person September 12-14, 2022, in New York City.

Arbutus Biopharma Corporation announced that the Company will participate in the following upcoming investor conferences taking place in New York.

Cognition Therapeutics, Inc. announced that members of management will be participating in two investment conferences in September 2022.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that the U.S. Food and Drug Administration (FDA) has awarded an Orphan Products Development grant to support the evaluation of HyBryte™ (synthetic hypericin) for expanded treatment in patients with early-stage CTCL.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company’s latest updates at the H.C. Wainwright 24th Annual Global Investment Conference.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference.

Medical robotics innovator Noah Medical revealed the next physician-only review and evaluation of the Galaxy System will take place from October 16-19, 2022 at the The American College of Chest Physicians annual meeting in Nashville, TN.

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City.